Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.

Vera Therapeutics, a US-based immunological and inflammatory disease therapy developer spun out of Yale University, has filed for an $86.3m initial public offering. Founded in 2016, Vera is developing therapies for the treatment of immunological and inflammatory diseases. Its lead drug candidate, atacicept, blocks the production of antibodies that contribute to certain autoimmune diseases. Atacicept…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.